On the other hand, Th17 cells could modulate antitumor immune responses by recruiting immune cells into tumors, converting toward Th1 phenotype, or even activating CD8 T cells and producing IFN-γ.9 Recent data on DLBCL showed that aberrant Th17 cells were significantly associated with inferior survival of the patients.10 Therefore, therapeutic targeting OX40/OX40L interaction with downstream Th17 cells remains of great interest for exploring potential immunotherapeutic approaches in DLBCL. The gene discussed is CD8A; the disease is diffuse large B-cell lymphoma.